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Abstract
Critically ill patients whose course is complicated by acute kidney
injury often receive renal replacement therapy (RRT). For these
patients, initiation of RRT results in a considerable escalation in
both the complexity and associated cost of care. While RRT is
extensively used in clinical practice, there remains uncertainty
about the ideal circumstances of when to initiate RRT and for what
indications. The process of deciding when to initiate RRT in
critically ill patients is complex and is influenced by numerous
factors, including patient-specific and clinician-specific factors and
those related to local organizational/logistical issues. Studies have
shown marked variation between clinicians, and across institutions
and countries. As a consequence, analysis of ideal circumstances
under which to initiate RRT is challenging. Recognizing this limita-
tion, we review the available data and propose a clinical algorithm
to aid in the decision for RRT initiation in critically ill adult patients.
The algorithm incorporates several patient-specific factors, based
on evidence when available, that may decisively influence when to
initiate RRT. The objective of this algorithm is to provide a starting
point to guide clinicians on when to initiate RRT in critically ill adult
patients. In addition, the proposed algorithm is intended to provide
a foundation for prospective evaluation and the development of a
broad consensus on when to initiate RRT in critically ill patients.
Introduction
Acute kidney injury (AKI) is a well-recognized complication of
critical illness with an important impact on morbidity, mortality
and health resource utilization [1-5]. Renal replacement
therapy (RRT) is often required and represents a substantial
escalation in the complexity and cost of care for critically ill
patients with AKI [4]. Despite its extensive use in clinical
practice, there is uncertainty about the optimal time and
indications for initiation of RRT in the ICU [6]. Clearly, the
process involved in deciding when to initiate RRT in critically
ill adult patients is complex and can be influenced by
numerous factors, including patient-specific and clinician-
specific factors and those related to organizational/logistical
issues (Table 1). Indeed, studies have shown marked varia-
tion of practice between clinicians, and across institutions
and countries [7,8].
An evaluation of timing of RRT initiation has been the focus of
a number of clinical studies. These have recently been sum-
marized in a systematic review and meta-analysis [6,9-13].
Most of these studies have been small, retrospective or
secondary analyses, and have arbitrarily dichotomized the
study population into ‘early’ or ‘late’ RRT initiation based on
biochemical criteria, urine output criteria, or by ‘door-to-
dialysis’ time [14]. The meta-analysis by Seabra and
colleagues [12] also included five randomized trials. A pooled
analysis from these trials showed a non-statistically significant
trend towards reduced mortality with earlier initiation of RRT
(relative risk 0.64; 95% confidence interval (CI), 0.40 to 1.05,
P = 0.08). However, this pooled analysis only included data
from 270 patients, thus limiting its statistical power.
Accordingly, this limits the inferences about timing of RRT
initiation and prohibits a simple translation of such data easily
to the bedside to guide clinical management. While large
prospective studies are urgently needed, the currently
available data would indicate a potential benefit associated
with earlier initiation of RRT for those patients where RRT is
likely to be needed in terms of both survival and recovery of
kidney function [12,15].
Currently, there exists no broad consensus to guide clinicians
on this important issue. In fact, RRT initiation has been
repeatedly identified as a research priority [16-18].
Accordingly, we have developed an opinion-based clinical
algorithm to aid in the decision on when to consider initiation
of RRT in critically ill patients (Figure 1). The algorithm gives a
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more quantitative characterization of ‘timing’ and incorporates
several patient-specific factors, based on clinical evidence
when available, that may influence when to initiate RRT. We
adapt the terminology proposed by the Acute Kidney Injury
Network (AKIN): ‘illness trajectory’ refers to the pace of
clinical evolution of the patient, and AKI ‘trend’ refers to the
rate of clinical and/or biochemical changes (including urea
and creatinine) [16]. The objective of this algorithm is to
provide a starting point to guide clinicians on when to
consider use of RRT in adult critically ill patients. This algo-
rithm will not specifically address additional key issues in the
delivery of renal support, such as RRT modality (continuous
versus intermittent), mode (convection versus diffusion) and
dose delivery [17-20]. Importantly, the algorithm is also
intended to provide a starting point for further prospective
evaluation to understand the ideal time/circumstances for
when to initiate RRT that could, in due course, promote
higher quality of patient care and improved clinical outcomes.
Algorithm for initiation of renal replacement
therapy in critically ill patients
The first priority after a patient is admitted to ICU is
determination of whether there are absolute indications
and/or emergent need for RRT. A summary of proposed
absolute indications for RRT initiation, based on consensus,
is presented in Table 2 [16]. It is important, however, to
recognize that RRT initiation in these circumstances can
largely be viewed as ‘rescue therapy’ where delays may have
deleterious consequences for the patient. Moreover, these
indications are largely adapted from ‘classic conventional’
indications for RRT in end-stage kidney disease, wherein the
main objective is alleviation of uremic complications.
Since AKI is common in critical illness, in the absence of
absolute indications for RRT, the next logical step is to
determine whether patients have AKI. In a multi-center multi-
national study, Uchino and colleagues [4] found AKI occurred
in 5 to 6% of all ICU admissions, with 70% of these even-
tually receiving RRT. Recent data indicate the incidence of
AKI is rising [21-23]. Historically, however, establishing
incidence estimates of AKI has been problematic due to the
lack of a standardized definition. Fortunately, a consensus-
driven classification scheme for AKI, the RIFLE criteria (and
modified AKIN criteria), has been recently proposed, which
represents a noteworthy advance for clinical practice and
research in AKI [24,25]. The RIFLE criteria have been
validated and proven robust for clinically relevant outcomes in
patients with AKI across numerous studies [3,5,26-29].
Epidemiologic studies of AKI, when defined by the RIFLE
criteria, have shown that 11 to 67% of ICU patients may
develop AKI during their illness course [29].
The RIFLE/AKIN criteria and initiation of
renal replacement therapy
The RIFLE criteria were initially developed to standardize the
diagnosis, classify the severity and monitor progression of
AKI. Importantly, they were also designed to enable better
comparison of clinical studies on the epidemiology and
attributable outcomes for AKI [24]. Currently, there is no
consensus on how to define timing of RRT initiation due to
the aforementioned limitations in available data. The concept
of ‘timing’ remains poorly defined and inconsistent [16].
Previously, timing of RRT has mostly been described by
qualitative criteria (early versus late/delayed). The RIFLE/AKIN
criteria provide the possibility of a more ‘quantitative’
characterization of timing. We recognize that these criteria
have not been formally evaluated as a tool for guiding
clinicians on when to initiate RRT. Yet, data from numerous
observational studies have consistently shown that earlier
initiation of RRT (however defined) correlated with improved
survival. This would appear to provide some justification of
‘early’, or perhaps a better term could be ‘timely’, RRT
initiation in selected critically ill patients with AKI. However,
further investigation, preferably by prospective randomized
trials, is undoubtedly warranted. A prospective analysis of the
impact of RRT initiation incorporating the RIFLE/AKIN
classification schemes on survival and renal recovery is a
potential starting point. Can these criteria have bedside utility
to aid in clinical decision-making? We believe this is a logical
first step in understanding how research evidence may be
translated into clinical practice to improve outcomes in
patients with AKI.
The RIFLE/AKIN criteria are also able to classify AKI severity
and follow trends over time [29]; both are vital to consider in
the context of RRT initiation. They are also a tool for dynamic
Table 1
Summary of selected factors potentially influencing the
decision to initiate renal replacement therapy in critically ill
patients
Factors
Patient-specific Kidney function/reserve
Co-morbid disease and physiologic reserve
Primary diagnosis: severity of illness and 
trajectory
Acute kidney injury: severity and trend
Clinician-specific Goals of therapy
Relative indications and clinician threshold for 
initiation
Local practice patterns
Prescribing service
Organizational Country/institution
ICU type
Machine and nursing availability
Health costsAvailable online http://ccforum.com/content/13/6/317
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Figure 1
Algorithm for initiation of renal replacement therapy in critically ill patients. *‘Optimized resuscitation’ of the kidney should also include
discontinuation/withholding nephrotoxic medications and anti-hypertensive medications that may exacerbate kidney function. §Exogenous toxins
(see [56]) and selected endogenous toxins (for example, myoglobin; see text). AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; RRT,
renal replacement therapy.evaluation of response to initial (non-RRT) therapy. We
emphasize again this algorithm is not intended to direct all
aspects of initial resuscitation and supportive therapy, but
rather provide an outline for when to consider RRT initiation.
Recent comprehensive reviews, based on consensus, have
summarized strategies for initial management of AKI [30].
Initiation of renal replacement therapy: risks versus
benefits
Initiation of RRT is not without risk for adverse consequences,
including hypotension (and exacerbation of kidney injury),
bleeding (depending on the anticoagulant used), dialysis
catheter-related complications, and exposure of patient blood
to an extracorporeal circuit. In addition, earlier initiation of
RRT has the potential to expose patients to this therapy who
may have otherwise spontaneously recovered kidney function
and/or survived without having received it. This issue,
however, is complicated by a paucity of data in critically ill
patients with AKI investigating factors that reliably predict
whether recovery of kidney function will occur (that is, partial
recovery or RRT-free) and whether this can be modified by
earlier RRT initiation. We believe this is a research priority.
Therefore, recognizing these gaps in knowledge are
important along with carefully weighing the potential risks of
RRT initiation against the goals of therapy and proposed
benefits.
Severe and/or acutely worsening acute kidney injury
In the presence of severe AKI (that is, RIFLE category F or
AKIN category III) and/or rapidly deteriorating kidney function,
we would consider RRT initiation, particularly if there was
failure to respond to initial therapy [30]. Data to support
earlier RRT in these patients is largely generated from
observational data [3,5,31]. In a single-centre retrospective
study of 5,383 critically ill patients, Hoste and colleagues [3]
found that of those developing RIFLE class R, 56%
progressed to either class I or F, and of those developing
RIFLE class I, 36% progressed to RIFLE class F. Patients
achieving RIFLE class F had a far worse clinical outcome,
characterized by an adjusted hazards ratio for hospital death
of 2.7 (95% CI, 2.0 to 3.6) and longer durations of stay in
both ICU and hospital. Yet, of these RIFLE class F patients,
only 14.2% received RRT. However, no specific analysis was
performed in this study to explore whether the higher
mortality for this group (RIFLE class F) was modified by
earlier RRT initiation. Bell and colleagues [31] performed a
7-year retrospective analysis of 207 patients with AKI
receiving RRT. When stratified by RIFLE class at the time
RRT was initiated, those with RIFLE class F had considerably
higher 30-day mortality when compared to those initiating
RRT at either RIFLE class R or I (adjusted hazards ratio 3.4;
95% CI, 1.2 to 9.3; crude 30-day mortality, 57.9% for F
versus 23.5% for R versus 22.0% for I). The RIFLE/AKIN
class should not likely be used in isolation to decide on when
to initiate RRT - but rather together with the overall goals of
therapy along with weighing of other relevant clinical
variables. We recognize that additional prospective
evaluation on this issue is needed to guide clinical practice;
however, in many circumstances, the risks of not providing
RRT may exceed those of initiation of RRT.
Mild to moderate acute kidney injury
The decision of if, and when, to initiate RRT in critically ill
patients with mild-moderate AKI (that is, RIFLE category R/I
or AKIN category I/II) is often the most challenging. It is
important to recognize that the decision to initiate RRT in
these patients is most likely to be multi-factorial and unlikely
to be made for any single indication. Several baseline factors
should be considered in these patients, including goals of
therapy, primary diagnosis, illness severity, baseline kidney
function/reserve and the need to potentially anticipate and
prevent complications that may be compounded in the
presence of AKI. Primary diagnoses associated with high
catabolic rates (that is, septic shock, major trauma, burn
injury) or those likely to place considerable demand on kidney
function (that is, gastrointestinal bleeding, rhabdomyolysis)
should be identified in the context of potential need for earlier
initiation of RRT.
Dynamic factors
Likewise, several ‘dynamic’ factors, including the trends in
AKI and/or illness severity, warrant consideration. Acute
and/or rapid changes in clinical status, such as whether AKI
is progressing (and how rapidly), the probability of kidney
recovery, whether illness severity is progressing (and how
rapidly), and additional measures of acute physiology such as
fluid accumulation [32], relative oliguria (that is, urine output
>200 ml/12 h, but insufficient to prevent fluid accumulation)
and the trajectory of non-kidney organ dysfunction should
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Table 2
A summary of absolute or ‘rescue therapy’ indications for
initiation of renal replacement therapy in critically ill patients
Category Characteristic
Metabolic
Azotemia Serum urea ≥36mmol/L (100 mg/dL)
Uremic complications Encephalopathy, pericarditis, bleeding
Hyperkalemia K+ ≥6 mmol/L and/or 
electrocardiogram abnormalities
Hypermagnesemia ≥4 mmol/L and/or anuria/absent deep 
tendon reflexes
Acidosis Serum pH ≤7.15
Oligo-anuria Urine output <200mL/12 h or anuria
Fluid overload Diuretic-resistant organ edema (that is, 
pulmonary edema) in the presence of 
acute kidney injury
Adapted from [16].factor into the decision of when to initiate RRT for those with
established mild-moderate AKI.
Co-interventions
Certain co-interventions in the ICU will also influence the
decision to initiate RRT in patients with mild to moderate AKI
[33]. For example, co-interventions may contribute to urea or
fluid accumulation, or systemic acidemia, therefore placing a
greater demand on already compromised kidney function. The
use of adjuvant corticosteroids in severe sepsis/septic shock is
common and can aggravate protein catabolism and azotemia
[34]. The increased urea generation coupled with retention of
uremic solutes may create a circumstance where RRT initiation
may need to be considered in those with mild-moderate AKI.
The concept of early goal-directed therapy as a guide for
acute resuscitation in septic shock has represented a signifi-
cant philosophical shift in the management of these patients
[35,36]. A key component of early goal-directed therapy is
the administration of fluid therapy, ideally targeted to
physiologic endpoints. In the trial by Rivers and colleagues
[36], enrolled patients received an estimated 13 to 14 liters
of fluid therapy in the first 72 hours (most within the initial
6 hours). While this trial did not provide data on AKI
occurrence, oliguria or fluid balance, septic patients are
known to be at high risk for AKI [37,38]. In this context, co-
existent or rapidly evolving AKI results in impaired free water
and solute excretion, and contributes to rapid fluid accumu-
lation and metabolic acidosis (especially with high chloride
containing solutions). These complex and integrated condi-
tions present a circumstance where earlier RRT may prove
beneficial. Diuretic therapy can be a useful adjunct for
management of fluid accumulation; however, their use in
patients with AKI should not delay RRT initiation with the
intent of avoiding RRT. In one study, diuretic use was
associated with increased mortality and non-recovery of
kidney function, which may have occurred in part due to
delayed initiation of RRT [39].
Critically ill patients with acute lung injury/acute respiratory
distress syndrome receiving lung-protective ventilation may
intentionally develop respiratory acidosis due to permissive
hypercapnea [40]. Co-existent and/or evolving AKI in these
patients will significantly impair capacity for kidney bicar-
bonate regeneration to buffer systemic acidemia. Earlier RRT
may prove beneficial in these patients prior to the
development of severe acidemia, worsening acute respiratory
distress syndrome and/or volume overload.
Non-kidney and other potential factors
influencing initiation of renal replacement
therapy
This list of potential ‘non-kidney’ indications for initiation of
RRT in critically patients continues to grow [16]. In this
context, the term extracorporeal blood purification (EBP),
rather than RRT, may be more appropriate.
Refractory septic shock
The use of EBP in sepsis is controversial. In particular, high-
volume hemofiltration has been advocated as a potential
adjuvant immunomodulatory therapy in refractory septic
shock by some consensus groups [41,42] but not others
[35]. Several small clinical trials have shown promising
results for improvements in hemodynamics, metabolic para-
meters and survival [43-45]. In their consensus statement the
Acute Dialysis Quality Initiative (ADQI) Working Group
concluded that the use of EBP in sepsis has biological
rationale that merits further investigation. While confirmatory
data from multi-center randomized trials are needed to inform
clinical practice on this issue, the authors believe that
patients with refractory septic shock may benefit from high-
volume EBP [41].
Fluid overload or accumulation
A positive fluid balance and overt clinical fluid overload, in
particular when refractory to medical therapy (that is,
diuretics), is also an important circumstance where RRT
initiation may prove beneficial [46]. In critically ill patients,
fluid overload may be under-recognized as an important
contributor to morbidity and mortality [32,47-51]. Longer
duration of mechanical ventilation, weaning failure, delayed
tissue-healing, and cardiopulmonary complications have all
been associated with fluid overload [50-52]. Likewise, a
positive fluid balance has been shown to predict mortality in
critically ill adults, an association likely modified by AKI
[47,48]. This significant and independent association between
fluid overload and mortality has been further revealed in
numerous clinical studies of critically ill children receiving
continuous RRT [53-55]. These data collectively present an
argument that fluid balance is an important biomarker in
critical illness [46]. RRT initiation should therefore be viewed
as a potentially important therapeutic measure, not only for
treatment of refractory fluid overload, but also for the
prevention of excessive fluid accumulation that may
contribute to worse clinical outcomes.
Toxins
Although considered controversial, EBP for selected toxins is
not infrequently performed [56]. EBP is more likely when the
intoxication is complicated by kidney dysfunction, which may
further reduce clearance of the toxin and/or its metabolites. In
addition to the exogenous toxins, EBP can also be performed
to aid in clearance of selected endogenous toxins, particularly
in the context of concomitant kidney dysfunction (that is,
rhabdomyolysis, tumor lysis syndrome). Electrolyte distur-
bances and metabolic acidosis induced by certain toxins can
also be readily corrected with EBP. Drug and toxin clearance
is influenced by several factors, including molecular weight,
volume of distribution, degree of protein binding, and water
solubility. It is beyond the scope of this review to discuss
details of indications and/or prescription of EBP for
overdoses/intoxications. Recent comprehensive reviews have
been published [56].
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RRT initiation for ‘non-kidney’ indications may also be
considered as a therapeutic and/or supportive treatment for
several other conditions such as severe electrolyte distur-
bances (that is, acid-base, dysnatremia) or disorders of
thermoregulation. Likewise, RRT can theoretically serve as an
adjuvant therapy for interrupting non-kidney organ dysfunc-
tion (that is, acute lung injury, congestive heart failure) and
attenuating pathologic organ crosstalk [57,58].
It is important to recognize, however, there are numerous,
often co-existent, physiologic and clinical insults occurring in
critically ill patients that have the potential to negatively
impact kidney function (that is, elevated intra-abdominal
pressure, mechanical ventilation with elevated positive end-
expiratory pressure (PEEP), nephrotoxins, radiocontrast
media). Likewise, the early detection of AKI is an obvious
clinical priority; however, current diagnostic methods rely on
conventional biomarkers and urine output. These are not
ideal, fail to reflect real-time declines in glomerular filtration,
and provide no data on whether a genuinely injurious process
to the kidney has occurred [6,59]. More importantly, these
conventional biomarkers require time to accumulate and can
translate into delayed recognition of AKI [6,59]. Accordingly,
while a patient may not (yet) fulfill the RIFLE criteria for AKI,
impaired kidney function may still be present, evolving and
undetected. The introduction of novel biomarkers for AKI will
hopefully advance this area [60]. As more definitive data
become available, incorporation of these biomarkers into the
decision-making process is likely.
Conclusions
Critically ill patients whose course is complicated by AKI
often receive RRT. RRT is an important therapeutic and
supportive measure and is commonly used in clinical
practice. However, there remains uncertainty about the ideal
circumstances in which to initiate RRT and for what
indications. The process of deciding when to initiate RRT in
critically ill patients is complex and can be influenced by
numerous factors. Currently, there exists large variation in
clinical practice between clinicians and across institutions
and countries, due, in part, to the lack of consensus on this
issue. We have proposed a clinically based algorithm to aid in
the decision on when to initiate RRT in critically ill patients
that incorporates patient-specific factors and based on
available clinical evidence. The intent of this algorithm is to
provide a starting point to guide clinicians on when to
consider initiation of RRT in critically ill patients and provide a
foundation for further prospective evaluation and
development of broad consensus on this important issue.
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